SCHEMBL2234693

SCHEMBL2234693

OCc1ncn2c1COc1ccccc1-2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRG2 P18507 10/20 0.54
GABRB3 P28472 10/20 0.54
GABRA5 P31644 10/20 0.54
GRM5 P41594 8/20 0.54
GABRP O00591 6/20 0.54
GABRD O14764 6/20 0.54
GABRA1 P14867 6/20 0.54
GABRB1 P18505 6/20 0.54
GABRA3 P34903 6/20 0.54
GABRA2 P47869 6/20 0.54
GABRB2 P47870 6/20 0.54
GABRA4 P48169 6/20 0.54
GABRE P78334 6/20 0.54
GABRA6 Q16445 6/20 0.54
GABRG1 Q8N1C3 6/20 0.54
GABRG3 Q99928 6/20 0.54
GABRQ Q9UN88 6/20 0.54
HSD17B3 P37058 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3954787 0.77 GABRG2 (0.58) GABRG2GABRB3GABRA5GRM5GABRP
SCHEMBL2234469 0.76 SRD5A1 (0.40) GABRG2GABRB3GABRA5HSD17B3MEN1
SCHEMBL2233575 0.73 GABRG2 (0.54) GABRG2GABRB3GABRA5GRM5GABRP
SCHEMBL2238273 0.73 SMN1; SMN2 (0.39) MEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL3950470 0.73 GABRG2 (0.69) GABRG2GABRB3GABRA5GRM5GABRP
SCHEMBL2235078 0.73 GRM5 (0.43) GABRG2GABRB3GABRA5GRM5GABRP
SCHEMBL2233633 0.71 GABRG2 (0.59) GABRG2GABRB3GABRA5GABRA1GABRA3
SCHEMBL5186663 0.70 GABRG2 (0.78) GABRG2GABRB3GABRA5GRM5GABRP
SCHEMBL3950799 0.70 GABRG2 (0.72) GABRG2GABRB3GABRA5GRM5GABRP
SCHEMBL6197153 0.70 GRM5 (1.00) GABRG2GABRB3GABRA5GRM5GABRP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110213143-A1 COMPOUND HAVING TAFIA INHIBITORY ACTIVITY TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-09-01 US disclosed
EP-2361910-A1 COMPOUND HAVING TAFIA INHIBITORY ACTIVITY Taisho Pharmaceutical Co., Ltd. (JP) 2011-08-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110213143-A1 COMPOUND HAVING TAFIA INHIBITORY ACTIVITY TAF1, TAF5, TAF11 GABRG2 2731/4885GABRB3 1763/4885GABRA5 1685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.